Nearly 5 Million Veterans Have Tried Psychedelics, RAND Study Finds
Nearly 5 million U.S. veterans have used psilocybin mushrooms, LSD or MDMA at least once in their lives, according to a new RAND report. The finding puts real numbers behind a shift already visible in policy debates, clinical research and veteran advocacy. Psychedelics are no longer a fringe topic among veterans. They are part of the lived experience of millions, even as federal rules and medical guidance remain unclear.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and  ketamine clinics closest to you as well as other psychedelic therapies in your area.
Key Takeways
| Key takeaway | Why it matters |
|---|---|
| 4.8 million veterans have used psilocybin, LSD or MDMA | Psychedelic use is not rare in this population. The scale makes policy clarity more urgent. |
| Psilocybin drew the most legal support | Nearly one in four veterans supported legal psilocybin use, more than LSD or MDMA. |
| Support changes by substance | Veterans appear to view mushrooms differently from LSD or MDMA, which matters for policy and education. |
| Many veterans are unsure about VA rules | Nearly half were unsure whether talking to a VA doctor about psychedelic use could affect benefits. |
| Past year use remains low | Lifetime use is common, but recent use was under 3 percent for every substance studied. |
| Veterans support FDA based access | About half supported VA coverage for psilocybin or MDMA therapy if the FDA approves it. |
Why The Numbers Matter
The RAND report comes at a moment when psychedelic research is moving deeper into veteran health. The Department of Veterans Affairs has begun supporting new studies of psychedelic assisted therapy for PTSD, depression and alcohol use disorder. Lawmakers have also pressed for more research and access.
That makes the new data important. The report does not just show interest. It shows exposure. Roughly 27 percent of veterans surveyed had used psilocybin, LSD or MDMA at some point. That translates to about 4.8 million people.
For clinicians and policymakers, this creates a practical problem. Veterans may already be using these substances outside formal care. Yet many do not know whether they can talk about it openly with a VA provider.
The VA Communication Gap
One of the most striking findings was not about use. It was about uncertainty.
RAND found that 48 percent of veterans were unsure whether discussing psilocybin use with a VA doctor could risk their benefits. For MDMA, the figure was 46 percent.
That kind of uncertainty can shape behavior. A veteran may avoid telling a clinician about psychedelic use. They may withhold information about dosing, timing or difficult experiences. They may also miss a chance to discuss drug interactions, mental health risk or safer decision making.
This is where policy becomes clinical. If patients fear consequences, doctors lose important information.
Psilocybin Stands Apart
Veterans did not view all psychedelics the same way. Nearly one in four supported legal use of psilocybin mushrooms. Support dropped to 11 percent for LSD and 9 percent for MDMA.
That split matters. Public conversations often group psychedelics together, but patients and voters may not. Mushrooms carry one set of cultural meanings. LSD and MDMA carry others.
The same distinction may influence future VA policy. If FDA approved therapies emerge, education will need to separate clinical evidence from reputation.
What This Does Not Show
The report should not be read as proof that psychedelics are safe or effective for veterans. It was a survey of use and attitudes, not a treatment trial.
It also does not show that most veterans are currently using psychedelics. Past year use was rare, below 3 percent for every substance studied.
That distinction matters. Lifetime use tells us psychedelics are familiar to many veterans. Recent use tells a more restrained story.
The Bigger Takeaway
The RAND report gives shape to a conversation that has often relied on anecdotes. Veterans are not waiting on policy before encountering psychedelics. Many have already used them, and many want clearer rules if therapies reach FDA approval.
The next step is not hype. It is clarity. Veterans need honest information, providers need guidance and the VA needs policies that encourage disclosure without fear. Psychedelic medicine may still be emerging, but the communication gap is already here.
